C4 Therapeutics



HBM contact: Dr Ivo Staijen, Dr Chandra P. Leo

Company status: public

C4 Therapeutics is developing small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell.  This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171